Analysts Have Conflicting Sentiments on These Healthcare Companies: Henry Schein (HSIC), Dyadic International (DYAI) and Bioventus (BVS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Henry Schein (HSIC – Research Report), Dyadic International (DYAI – Research Report) and Bioventus (BVS – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Henry Schein (HSIC)
William Blair analyst Brandon Vazquez maintained a Hold rating on Henry Schein today. The company’s shares closed last Monday at $81.87, close to its 52-week high of $82.49.
According to TipRanks.com, Vazquez is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $87.92 average price target, implying an 8.8% upside from current levels. In a report issued on February 25, TipRanks – OpenAI also downgraded the stock to Hold with a $90.00 price target.
See today’s best-performing stocks on TipRanks >>
Dyadic International (DYAI)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Dyadic International. The company’s shares closed last Monday at $0.78.
According to TipRanks.com, Hewitt has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Dyadic International has an analyst consensus of Moderate Buy.
Bioventus (BVS)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Bioventus today. The company’s shares closed last Monday at $8.54.
According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of
Currently, the analyst consensus on Bioventus is a Strong Buy with an average price target of $14.00.
